Here are three report insights.
1. Valeant’s revenues fell 12.9 percent from $2.79 billion to $2.40 billion. The quarter is Valeant’s third consecutive quarter of double-digit losses.
2. Valeant’s net losses increased to $515 million in Q4.
3. Valeant has been attempting to “rebuild its business and regain investor confidence,” after an investigation into its accounting and pricing methods, Reuters reports.
More articles on gastroenterology/endoscopy:
Comparing primary care to concierge core: Which is more costly?
Study: Physicians & NPs, PAs provide equal quality of care
Gainesville Endoscopy Center’s new location to open its doors: 4 notes
